Abrégé

A medicated diet composition for treating a heat cough, prepared from the raw materials in the following parts by mass: 50-100 parts of kumquat, 30-50 parts of Eleocharis dulcis, 5-10 parts of Glehniae radix and 5-10 parts of Platycodonis radix. The medicated diet composition can improve the symptoms of a heat cough of a SARS-CoV-2 infection.

Classes IPC  ?

• A61K 36/89 - Cyperaceae (famille de la laîche)
• A61K 36/75 - Rutaceae (famille de la rue)
• A61K 36/34 - Campanulaceae (famille de la campanule)
• A61K 36/23 - Apiaceae ou Umbelliferae (famille de la carotte), p. ex. aneth, cerfeuil, coriandre ou cumin
• A61P 11/14 - Antitussifs
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés

Abrégé

The present invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a medicated diet composition for treating a cold cough, and a preparation method therefor and the use thereof. The medicated diet composition of the present invention comprises the raw materials in the following parts by mass: 50-100 parts of kumquat, 10-20 parts of fresh ginger, 2-3 parts of Citri reticulatae pericarpium and 5-10 parts of Platycodonis radix. The medicated diet composition of the present invention can quickly improve the symptoms of a cold cough of a SARS-CoV-2 infection, and is particularly suitable for patients with a cold cough of a SARS-CoV-2 infection in regions where drug resources are relatively short, medical resources are relatively poor and the purchase of drugs is relatively difficult.

Classes IPC  ?

• A61K 36/9068 - Zingiber, p. ex. gingembre
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A61P 11/14 - Antitussifs
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61P 11/04 - Médicaments pour le traitement des troubles du système respiratoire des maux de gorge
• A61P 11/10 - Expectorants

Abrégé

Provided are a traditional Chinese medicine composition for tonifying Qi, activating blood and detoxificating and use thereof. The composition is prepared from the following ingredients: 10-30 parts of sun-dried ginseng, 6-30 parts of pseudo-ginseng, and 3-15 parts of Rheum officinale. The traditional Chinese medicine composition can ameliorate the illness state of patients suffering from sepsis secondary to pulmonary infection, and the oxygen saturation of the patients is improved by means of bowel-relaxing and anti-inflammation effects, thus shortening the mechanical ventilation time of the patients.

Classes IPC  ?

• A61K 36/708 - Rheum (rhubarbe)
• A61K 36/258 - Panax (ginseng)
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 31/04 - Agents antibactériens

Abrégé

Disclosed in the present invention is a new triptolide derivative as shown in formula (I). Also disclosed in the present invention are a preparation method for the compound and the medical use thereof in preparation of anti-cancer drugs. Triptolide acrylate of the present invention and a pharmaceutically acceptable salt thereof have anti-cancer activity, and after animal in-vivo experiments, can effectively inhibit tumor growth in animals. A plurality of in-vitro experiments proves that same can significantly increase the protein expression quantity of p53, promote the apoptosis of tumor cells, effectively inhibit the growth of the tumor cells, and have the effect of inhibiting metastasis of cancer cells. More importantly, the toxicity of the compound to normal cells is less than that of triptolide.

Classes IPC  ?

• A61K 31/365 - Lactones
• A61P 35/00 - Agents anticancéreux
• C07J 73/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène modifié par substitution d'un ou deux atomes de carbone par des hétéro-atomes

Abrégé

A traditional Chinese medicine for the treatment of diabetic nephropathy, comprising the following raw materials in parts by weight: 9-30 parts of radix astragali, 6-15 parts of semen cuscutae, 5-10 parts of peach kernel, 3-10 parts of rhizoma atractylodis, 3-10 parts of dried tangerine peel, 15-30 parts of centella asiatica, and 3-10 parts of cordyceps cicadae.

Classes IPC  ?

• A61K 36/752 - Citrus, p. ex. citron vert, orange ou citron
• A61K 35/64 - Insectes, p. ex. abeilles, guêpes ou puces
• A61P 37/02 - Immunomodulateurs
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
• A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques

Abrégé

The present invention belongs to the field of traditional Chinese medicine, and in particular, to a composition for preventing rheumatoid arthritis, a preparation method therefor, and an application thereof. The composition for preventing rheumatoid arthritis of the present invention is prepared from the following raw material components in parts by mass: 15-60 parts of raw Semen Coicis, 5-30 parts of Radix Angelicae Sinensis, 5-30 parts of Radix Paeoniae Alba, 1-15 parts of Herba Ephedrae, 5-30 parts of Ramulus Cinnamomi, 5-30 parts of Radix Glycyrrhizae Praeparata, 5-30 parts of Rhizoma Atractylodis, and 10-60 parts of Radix Astragali. Proved by a CIA rat model experiment, the composition for preventing rheumatoid arthritis of the present invention can obviously alleviate the joint swelling degree of a CIA rat, X ray shows that bone destruction can be improved, and a pathological section shows good effects of inhibiting synovial tissue proliferation, reducing inflammatory cell infiltration, and delaying bone and cartilage destruction, thereby achieving the effects of symptom improvement, bone protection and anti-inflammatory for the CIA rat.

Classes IPC  ?

• A61K 36/8994 - Coix (Lacrimia Jobi)
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

A composition for preventing and/or treating rheumatoid arthritis, a preparation method therefor, and an application thereof. The composition is made from the following raw material components in parts by mass: 10-40 parts of Radix Salviae Miltiorrhizae, 15-120 parts of Rhizoma Dioscoreae Nipponicae, 15-60 parts of Radix Astragali, 5-30 parts of Radix Paeoniae Alba, 3-15 parts of Ephedra, 3-15 parts of Radix Aconiti Laterailis Prepareata, 5-30 parts of Morinda Officinalis, and 5-30 parts of honey-fried licorice root. By means of clinical tests, it is proven that said composition can alleviate the symptoms of articulation swelling and suffered by patients, control the level of inflammation and disease progression, and has potential bone protection effects.

Classes IPC  ?

• A61K 36/8945 - Dioscorea, p. ex. igname, Dioscorea opposita ou Dioscorea alata
• A61K 36/746 - Morinda
• A61K 36/714 - Aconitum (aconit)
• A61K 36/71 - Ranunculaceae (famille du bouton d'or), p. ex. pied d'alouette, hépatique, hydrastis, ancolie
• A61K 36/65 - Paeoniaceae (famille de la pivoine), p. ex. pivoine chinoise
• A61K 36/537 - Salvia (sauge)
• A61K 36/484 - Glycyrrhiza (réglisse)
• A61K 36/481 - Astragalus (astragalus cicer)
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• A61P 19/08 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget

Abrégé

The present invention belongs to the field of traditional Chinese medicines, and in particular relates to a composition for preventing and/or treating rheumatoid arthritis, a preparation method therefor and an application thereof. The composition for preventing and/or treating rheumatoid arthritis of the present invention is prepared from the following raw material components in parts by mass: 5-30 parts Notopterygium root, 5-45 parts kadsura pepper stem, 3-20 parts of prepared aconite root, 5-30 parts of Gentiana macrophylla, 5-30 parts of ramulus mori, 5-30 parts of Angelica sinensis, 5-20 parts of Ligusticum wallichii, 3-15 parts of Costustoot, and 3-30 parts of Radix glycyrrhizae preparata. According to clinical trials, the composition for preventing and/or treating rheumatoid arthritis of the present invention can improve the symptoms of joint swelling and pain in patients, control inflammation levels and disease progression, and has potential bone protection effects.

Classes IPC  ?

• A61K 36/714 - Aconitum (aconit)
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

Disclosed in the present invention is an application of a glutaminase inhibitor in preparation of a drug for treating psoriasis. According to the present invention, in-vitro cell experiments prove that the glutaminase inhibitor can inhibit keratinocyte metabolism glutamine, inhibit miR-31 induced up-regulated keratinocyte mitochondrial respiration, inhibit miR-31 induced mTOR pathway, reduce cell activity and promote cell apoptosis, and has an anti-inflammatory effect; animal experiments prove that the glutaminase inhibitor can be used for effectively treating imiquimod-induced mouse psoriasis-like pathology change, comprising remarkably reducing a Baker score of a skin lesion, effectively reducing an epidermal hypertrophy degree, remarkably reducing the number of subepidermal capillaries, remarkably reducing the number of epidermal Ki67 positive cells and reducing the expression of epidermal GLS. Therefore, the glutaminase inhibitor can be used for preparing a drug for treating psoriasis.

Classes IPC  ?

• A61K 31/42 - Oxazoles
• A61K 31/501 - PyridazinesPyridazines hydrogénées non condensées et contenant d'autres hétérocycles
• A61K 31/473 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. acridines, phénantridines
• A61K 31/433 - Thiadiazoles
• A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
• A61P 17/06 - Antipsoriasiques

Abrégé

A traditional Chinese medicine composition for dispelling dampness and clearing the lung, comprising the following components in parts by mass: 5-10 parts of raw ephedra, 25-30 parts of raw gypsum, 5-12 parts of bitter almonds, 10-16 parts of rhizoma anemarrhenae, 10-16 parts of bupleurum chinense, 10-16 parts of notopterygium root, 10-16 parts of rhizoma atractylodis, 10-16 parts of agastache rugosa, and 5-12 parts of medicated leaven. The traditional Chinese medicine composition can treat community-acquired pneumonia, especially viral pneumonia, or suspected COVID 19 cases. When used as a treatment drug for suspected COVID 19 cases, thetraditional Chinese medicine composition can cut off and reverse the condition and prevent the condition from getting worse.

Classes IPC  ?

• A61K 36/8964 - Anemarrhena
• A61K 36/736 - Prunus, p. ex. prune, cerise, pêche, abricot ou amande
• A61K 36/532 - Agastache, p. ex. hysope
• A61K 33/06 - Aluminium, calcium ou magnésiumLeurs composés
• A61K 9/08 - Solutions
• A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
• A61K 9/16 - AgglomérésGranulésMicrobilles
• A61K 9/20 - Pilules, pastilles ou comprimés
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The present invention relates to a qi-tonifying, dampness-eliminating and sore-throat-relieving dietary therapy formula, and a preparation method therefor and an application thereof. The raw materials thereof comprise: 6-15 parts of sun-dried ginseng or American ginseng, 1-6 parts of dried orange peel, 1-3 parts of Chinese olives, 3-15 parts of fresh ginger, and 250-500 parts of lean meat. The preparation method comprises adding the raw materials according to proportions, adding water, heating to boiling by big fire, cooking for 8-12 minutes, and then changing to soft fire for cooking for 40-60 minutes. The dietary therapy formula of the present invention can serve as an effective component for preparing a qi-tonifying, dampness-eliminating and sore-throat-relieving agent, which is used for preparing a drug for treating viral asymptomatic infection, influenza, acute upper respiratory tract infection, chronic pharyngitis, or weakness.

Classes IPC  ?

• A61K 36/9068 - Zingiber, p. ex. gingembre
• A61K 36/752 - Citrus, p. ex. citron vert, orange ou citron
• A61K 36/32 - Burseraceae (famille de l'encens)
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61P 11/04 - Médicaments pour le traitement des troubles du système respiratoire des maux de gorge
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A23L 33/105 - Extraits de plantes, leurs doublons artificiels ou leurs dérivés
• A23L 33/10 - Modification de la qualité nutritive des alimentsProduits diététiquesLeur préparation ou leur traitement en utilisant des additifs
• A23L 23/00 - PotagesSauces Leur préparation ou leur traitement
• A23L 13/00 - Produits à base de viandeFarine de viandeLeur préparation et leur traitement
• A23L 13/50 - Produits à base de volaille, p. ex. saucisses à base de volaille
• A23L 17/00 - Produits tirés de la merProduits à base de poissonFarine de poissonSuccédanés d’œufs de poissonLeur préparation ou leur traitement

Abrégé

Provided is a traditional Chinese medicine composition capable of removing toxins, dispelling dampness, and disinhibiting the throat, comprising the following components in parts by mass: 15-35 parts of raw Semen Coicis, 10-15 parts of Flos Lonicerae, 10-15 parts of Folium Perillae, 10-30 parts of Radix Scrophulariae, 10-20 parts of Radix Platycodi, 15-30 parts of Radix Pseudostellariae, 5-15 parts of Rhizoma Atractylodis, and 5-15 parts of Herba Pogostemonis. The composition is used for treating asymptomatic SARS-CoV-2 infection cases, symptoms such as cough, dry throat, itchy throat, sore throat, and hoarseness caused by chronic pharyngitis, and fever, cough, dry throat, itchy throat, sore throat, hoarseness, fatigue, etc. caused by influenza and acute upper respiratory tract infections.

Classes IPC  ?

• A61K 36/8994 - Coix (Lacrimia Jobi)
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 11/04 - Médicaments pour le traitement des troubles du système respiratoire des maux de gorge
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus

Abrégé

Provided are a traditional Chinese medicine composition and the use thereof in the preparation of a drug for treating viral diseases, especially SARS-CoV-2 asymptomatic infection cases, influenza, acute upper respiratory tract infections, and chronic pharyngitis. The traditional Chinese medicine composition comprises, in parts by mass: 25-35 parts of Ilex asprella radix, 5-10 parts of Menthae haplocalycis herba, 15-25 parts of Mume fructus and 10-20 parts of Atractylodis rhizoma.

Classes IPC  ?

• A61K 36/736 - Prunus, p. ex. prune, cerise, pêche, abricot ou amande
• A61K 36/534 - Mentha (menthe)
• A61K 36/284 - Atractylodes
• A61K 36/185 - Magnoliopsida (dicotylédones)
• A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• A61P 11/04 - Médicaments pour le traitement des troubles du système respiratoire des maux de gorge
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire

Abrégé

The present invention relates to the technical field of traditional Chinese medicines, and relates to a pharmaceutical composition for strengthening the body and treating lung diseases, comprising the following components in parts by mass: 10-30 parts of cooked aconite, 5-15 parts of dried ginger, 20-30 parts of roasted licorice, 10-20 parts of honeysuckle, 10-30 parts of spina gleditsiae, 20-45 parts of hairy fig, 10-15 parts of patchouli, and 5-15 parts of dried tangerine peel. The present invention also provides application of the pharmaceutical composition for strengthening the body and treating lung diseases in the preparation of medicines for treating COVID-19. The pharmaceutical composition for strengthening the body and treating lung diseases of the present invention may have a certain effect in reversing the progression of severe and critical diseases of COVID-19 and lowering the rate of deterioration.

Classes IPC  ?

• A61K 36/9068 - Zingiber, p. ex. gingembre
• A61P 1/08 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des nausées, du mal des transports ou des vertigesAntiémétiques
• A61P 1/14 - Eupeptiques, p. ex. acides, enzymes, orexigènes, antidyspeptiques, toniques, antiflatulants
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

Disclosed in the present invention is a new triptolide derivative as shown in formula (I). Also disclosed in the present invention are a preparation method for the compound and the medical use thereof in the preparation of anti-cancer drugs. The triptolide acrylate of the present invention and pharmaceutically acceptable salts thereof have anti-cancer activity, and after animal in-vivo experiments, can effectively inhibit tumor growth in animals. A plurality of in-vitro experiments prove that same can significantly increase the protein expression quantity of p53, promote the apoptosis of tumor cells, effectively inhibit the growth of the tumor cells, and have the effect of inhibiting cancer cell metastasis. More importantly, the toxicity of the compound to normal cells is less than that of triptolide.

Classes IPC  ?

• C07D 493/22 - Composés hétérocycliques contenant des atomes d'oxygène comme uniques hétéro-atomes dans le système condensé dans lesquels le système condensé contient au moins quatre hétérocycles
• C07J 73/00 - Stéroïdes ayant le squelette du cyclopenta[a]hydrophénanthrène modifié par substitution d'un ou deux atomes de carbone par des hétéro-atomes
• A61K 31/365 - Lactones
• A61P 35/00 - Agents anticancéreux

Abrégé

Applications of psoralen in preparing an Nrf2 inhibitor, a medicament for Nrf2 inhibition-related diseases, and an anticancer medicament. Psoralen reduces the level of Nrf2 protein expression, reduces the antioxidative stress ability of human non-small cell lung carcinoma A549 cells, and increases the proapoptotic effects of chemotherapeutic medicament cisplatin with respect to A549. Psoralen has no significant impact on animal liver and kidneys when used as a medicament.

Classes IPC  ?

• A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
• A61K 33/243 - PlatineSes composés
• A61P 35/00 - Agents anticancéreux

Abrégé

A novel low-toxicity tripterygium glycoside, being obtained by chemical processing tripterygium glycoside and adding triptriolide. The novel low-toxicity tripterygium glycoside can effectively alleviate renal pathological damage and proteinuria in nephrotic syndrome, improve an inflammation level of the body, and has a significant therapeutic effect on nephrotic syndrome.

Classes IPC  ?

• A61K 36/37 - Celastraceae (famille du bourreau des arbres ou de la camarine), p. ex. tripterygium ou fusain
• A61P 37/02 - Immunomodulateurs
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
• A61P 19/08 - Médicaments pour le traitement des troubles du squelette des maladies osseuses, p. ex. rachitisme, maladie de Paget
• A61P 19/04 - Médicaments pour le traitement des troubles du squelette des troubles non-spécifiques du tissu conjonctif
• A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
• A61P 17/06 - Antipsoriasiques
• A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
• A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
• A61P 9/14 - VasoprotecteursAntihémorroïdauxMédicaments pour le traitement des varicesStabilisateurs capillaires
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques

Abrégé

The invention relates to a preparation method of new-type nanoparticles for loading emodin, which comprises: using L.A, mPEG and stannous iso caprylate to synthesize a first intermediate product; using the first intermediate product, butanedioic anhydride and 4-dimethylaminopyridine to synthesize a second intermediate product; using the second intermediate product, 1-ethyl-(3-dimethylamino propyl) carbodiimide hydrochloride, N-hydroxysuccinimide and chitosan to synthesize a third intermediate product; using the third intermediate product and sodium periodate to synthesize a fourth intermediate product; using the fourth intermediate product and 5-amino-2-mercapto benzimidazole to synthesize the new-type thiolated nanoparticles. The nanoparticles loaded with emodin are used for intestinal tract dose, which may enhance the nanoparticles' adhesion ability, prolong residence time of drugs on mucosal membranes, and facilitate sustained-release of drug molecules. The encapsulation efficiency after loading drugs is no less than 83.6%, the drug loading capacity is no less than 3.89%, and good water solubility and biological degradability are provided.

Classes IPC  ?

• C08K 5/378 - Sulfures contenant des hétérocycles
• C08B 37/08 - ChitineSulfate de chondroïtineAcide hyaluroniqueLeurs dérivés
• C08G 63/42 - Éthers cycliquesCarbonates cycliquesSulfites cycliquesOrthoesters cycliques
• C08L 67/04 - Polyesters dérivés des acides hydroxycarboxyliques, p. ex. lactones
• A61K 9/51 - Nanocapsules
• C08L 5/08 - ChitineSulfate de chondroïtineAcide hyaluroniqueLeurs dérivés
• C08G 63/664 - Polyesters contenant de l'oxygène sous forme de groupes éther dérivés d'acides hydroxycarboxyliques
• C08G 63/91 - Polymères modifiés par post-traitement chimique
• G01N 21/35 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p. ex. spectrométrie d'absorption atomique en utilisant la lumière infrarouge
• B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
• G01R 33/46 - Spectroscopie RMN